14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
NKTR vs VOR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
NKTR Captures Overall Composite Edge (61.1 BUY vs 57.8 HOLD), While VOR Leads 3–2 on Growth & Valuation Pillars
NKTR Overall Winner
6-Pillar Tally: NKTR 2 – 3 VOR (1 Tie)
Matrix Metrics: NKTR 5 – 5 VOR
As of Nov 16, 2026, Nektar Therapeutics (NKTR) captures the overall head-to-head institutional edge over Vor Biopharma Inc. (VOR) on higher Unified Composite conviction (61.1/100 BUY vs. 57.8/100 HOLD) after splitting the core matrix 5–5 (led by Valuation Multiples, Growth & Scale), while VOR wins 3–2 across the 6-pillar growth and valuation breakdown. NKTR trades at $36.57 (34.0x Forward P/E, -239.3% operating margin) versus VOR at $19.26 (N/M Forward P/E, 0.0% operating margin).
Growth vs. Quality Trade-Off: NKTR earns the overall head-to-head edge with a stronger Unified Composite Score (61.1/100 BUY vs. VOR 57.8/100 HOLD) and 1.10β · 48% Vol risk profile, whereas VOR leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: NKTR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.3); meanwhile VOR trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NKTR vs VOR. Trailing 12-month operating profitability (NKTR -239.3% vs VOR 0.0%) and valuation multiples (NKTR 34.0x vs VOR N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $1.3B market capitalization and -239.3% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
VOR Moat ProfileCyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.2B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ NKTR vs VOR Key Questions & Quantitative Answers
As of Nov 16, 2026, Nektar Therapeutics (NKTR) captures the overall head-to-head institutional edge over Vor Biopharma Inc. (VOR) on higher Unified Composite conviction (61.1/100 BUY vs. 57.8/100 HOLD) after splitting the core matrix 5–5 (led by Valuation Multiples, Growth & Scale), while VOR wins 3–2 across the 6-pillar growth and valuation breakdown. NKTR trades at $36.57 (34.0x Forward P/E, -239.3% operating margin) versus VOR at $19.26 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: NKTR earns the overall head-to-head edge with a stronger Unified Composite Score (61.1/100 BUY vs. VOR 57.8/100 HOLD) and 1.10β · 48% Vol risk profile, whereas VOR leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: NKTR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.3); meanwhile VOR trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
NKTR leads the Growth & Scale pillar: NKTR posts -9.3% YoY revenue growth and +0.0% YoY earnings growth on $55M TTM revenue (100.0% gross margin, -239.3% operating margin), compared with VOR at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, NKTR generates $55M in USD-normalized revenue versus N/A for VOR. In operating R&D and SG&A reinvestment, NKTR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VOR.
NKTR screens cheaper on headline valuation multiples. NKTR trades at 34.0x Forward P/E, 34.0x Trailing P/E, 0.31x PEG, and 24.0x EV/Revenue (unreported FCF margin), whereas VOR trades at N/M Forward P/E, 0.1x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NKTR (-35.8% ROE) versus VOR (-125.4% ROE) capital efficiency.
In options market volatility and institutional positioning, NKTR carries 76.9% implied volatility (5th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.10β · 48% Vol realized risk). By comparison, VOR carries 127.0% implied volatility (6th %ile, Compressed (<25th %ile)), a 2.03x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.91β · 61% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.